MEIRAGTX HOLDINGS PLC (MGTX) competitors & alternatives
Health Care · NASDAQ
MEIRAGTX HOLDINGS PLC (MGTX)'s top competitors and alternatives — its most similar public companies — include REGENXBIO INC (RGNX), Lilly (Eli) (LLY), Tenaya Therapeutics, Inc. (TNYA), NEUROGENE INC (NGNE), Gilead Sciences (GILD), SOLID BIOSCIENCES INC (SLDB), IMMIX BIOPHARMA INC (IMMX), CARIBOU BIOSCIENCES INC (CRBU), SUPERNUS PHARMACEUTICALS INC (SUPN), DENALI THERAPEUTICS INC (DNLI), OPUS GENETICS INC (IRD) and BEAM THERAPEUTICS INC (BEAM). These are MEIRAGTX HOLDINGS PLC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top MGTX competitors & alternatives
-
REGENXBIO INCRGNXHealth Care
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with…
$10.20 (as of 2026-07-22) · market cap $529M
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,163.01 (as of 2026-07-22) · market cap $1.09T
-
Tenaya Therapeutics, Inc.TNYAHealth Care
Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine…
$0.79 (as of 2026-07-22) · market cap $171M
-
NEUROGENE INCNGNEHealth Care
Neurogene is a clinical-stage gene therapy company utilizing proprietary transgene regulation technology to develop treatments for rare, devastating…
$36.11 (as of 2026-07-22) · market cap $721M
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
SOLID BIOSCIENCES INCSLDBHealth Care
A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's…
$8.10 (as of 2026-07-22) · market cap $808M
-
IMMIX BIOPHARMA INCIMMXHealth Care
Immix Biopharma is a clinical-stage CAR-T cell therapy company developing next-generation immunotherapies for relapsed/refractory light chain amyloidosis with…
$9.41 (as of 2026-07-22) · market cap $670M
-
CARIBOU BIOSCIENCES INCCRBUHealth Care
Caribou develops off-the-shelf CRISPR-engineered CAR-T cell therapies designed to make cellular immunotherapy faster, cheaper, and accessible to more blood…
$1.66 (as of 2026-07-22) · market cap $165M
-
SUPERNUS PHARMACEUTICALS INCSUPNHealth Care
Supernus is a biopharmaceutical company commercializing approved CNS treatments across ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine…
$46.94 (as of 2026-07-22) · market cap $2.8B
-
DENALI THERAPEUTICS INCDNLIHealth Care
Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the…
$23.64 (as of 2026-07-22) · market cap $3.7B
-
OPUS GENETICS INCIRDHealth Care
Clinical-stage biopharmaceutical company developing AAV-based gene therapies to restore vision in patients with inherited retinal diseases.
$3.05 (as of 2026-07-22) · market cap $252M
-
BEAM THERAPEUTICS INCBEAMHealth Care
Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare…
$26.64 (as of 2026-07-22) · market cap $2.7B
Not quite? Describe exactly what you want →
Peers are MEIRAGTX HOLDINGS PLC's closest public companies by shared sub-industry, sector and business themes. See the full profile: MEIRAGTX HOLDINGS PLC (MGTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.